What question did this study set out to answer?

The goal is to improve early diagnosis and classification of Inflammatory Bowel Disease (IBD) using serological profiling.

January 23, 2026Journal of Crohn s and Colitis

DOP017Unique serological signatures enable the diagnosis and stratification of Inflammatory Bowel Disease

View Full Paper

Ask AI

Bookmark

Authors

JCJ F ColombelKiel University SMS MehandruIcahn School of Medicine at Mount Sinai ALAlexandra E. LivanosIcahn School of Medicine at Mount Sinai

Discussion

Member takes

Implication

This research identifies unique serological signatures for diagnosing IBD and distinguishing between Crohn’s disease and Ulcerative Colitis, highlighting significant clinical implications.

Key Points

The goal is to improve early diagnosis and classification of Inflammatory Bowel Disease (IBD) using serological profiling.
Profiled sera from adult and pediatric cohorts with IBD and non-IBD using anti-microbial and autoantibody panels.
Determined cutoffs for positive antibody status based on healthy adults and manufacturer guidelines.
Employed logistic models to differentiate IBD from non-IBD and to stratify UC versus CD.
Validated model parameters across adult and pediatric cohorts.
In the adult cohort, AUCs were 0.85 for IBD vs non-IBD and 0.86 for CD vs UC.
Sensitivity for distinguishing IBD from non-IBD was 80% with specificity of 79%.
Among IBD samples, discrimination between UC and CD yielded sensitivity of 91% and specificity of 73%.
Pediatric cohort showed 80% sensitivity and 67% specificity for distinguishing IBD from non-IBD.

Cite This Study

Colombel et al. (2026) studied this question.

synapsesocial.com/papers/69730fe2c8125b09b0d1fa57 https://doi.org/10.1093/ecco-jcc/jjaf231.054

View Full Paper

Ask AI

Bookmark

Implication

This research identifies unique serological signatures for diagnosing IBD and distinguishing between Crohn’s disease and Ulcerative Colitis, highlighting significant clinical implications.